GO:0006956 complement activation: Immune Cascade, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006956 complement activation describes the biological process that triggers the complement cascade, leading to direct killing of microbes, clearance of immune complexes, and regulation of other immune responses.
• Three initiation pathways converge on complement activation: the classical pathway (antibody-antigen complexes), the alternative pathway (spontaneous C3 hydrolysis), and the lectin pathway (carbohydrate recognition).
• Dysregulated complement activation is a central driver in systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and other rheumatic diseases.
• Complement activation contributes to neurological disorders, pregnancy complications, and adverse reactions to drug carriers and nanoparticles.
• Key genes and proteins include C1QA, C1QB, C1QC, C1R, C1S, C2, C3, C4A, C4B, C5, CFB, CFD, CFH, CFI, MASP1, MASP2, MBL2, and CFP.
• CRISPR-based knockout, knock-in, point mutation, and overexpression models enable precise dissection of complement gene function in disease contexts.
Description
Complement activation (GO:0006956) is a fundamental biological process that initiates the complement cascade, a key component of innate immunity. This process allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes. The complement system is composed of over 30 plasma and membrane-bound proteins that interact in a tightly regulated manner to defend the host against infection and maintain immune homeostasis. Researchers study complement activation because its dysregulation is implicated in a wide range of human diseases, including autoimmune disorders, neurological conditions, and pregnancy complications. Understanding the molecular mechanisms of complement activation is essential for developing targeted therapies and diagnostic tools. The process is initiated through three distinct pathways: the classical pathway, the alternative pathway, and the lectin pathway, all of which converge on the terminal complement pathway. Each pathway is triggered by different stimuli and involves specific recognition molecules and proteases, but they share the common goal of opsonizing pathogens, recruiting inflammatory cells, and forming the membrane attack complex (MAC) to lyse target cells. This article provides a comprehensive overview of complement activation, covering its definition, mechanisms, key genes, disease associations, and research methodologies, with a focus on CRISPR-based approaches for functional studies.
complement activation At A Glance
| GO ID | GO:0006956 |
|---|---|
| GO term | complement activation |
| Ontology | biological_process |
| Synonym | complement activity, complement cascade, complement response |
| Major function | Direct killing of microbes, disposal of immune complexes, regulation of other immune processes |
| Pathways involved | Classical pathway, alternative pathway, lectin pathway, terminal pathway |
| Key proteins | C1q, C1r, C1s, C2, C3, C4, C5, factor B, factor D, MASP1/2, MBL, properdin |
| Regulation | Complement inhibitors such as C1-inhibitor, factor H, factor I, CD55, CD59, and C4BP |
| Disease relevance | SLE, antiphospholipid syndrome, neurological disorders, pregnancy complications, drug carrier reactions |
What Is GO:0006956?
Complement activation (GO:0006956) is defined as any process involved in the activation of any of the steps of the complement cascade, which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes. The initial steps of complement activation involve one of three pathways: the classical pathway, the alternative pathway, and the lectin pathway, all of which lead to the terminal complement pathway.
Why Is complement activation Important in Cell Biology?
Complement activation is critically important because it serves as a first line of defense against pathogens and plays a central role in immune surveillance and homeostasis. Dysregulation of this process is directly linked to the pathogenesis of numerous diseases, including autoimmune disorders such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), where excessive or uncontrolled complement activation leads to tissue damage and inflammation. In neurological disorders, aberrant complement activation contributes to synaptic pruning and neurodegeneration. During pregnancy, complement activation can threaten fetal viability and is associated with complications such as recurrent miscarriage and preeclampsia. Furthermore, complement activation by drug carriers and particulate pharmaceuticals can cause adverse reactions, highlighting the need for careful design of nanomedicines. Understanding the precise molecular events of complement activation is therefore essential for developing targeted therapies and for interpreting the effects of genetic variations in complement genes.
• Complement activation is a central effector mechanism of innate immunity, providing rapid defense against microbial infections.
• It facilitates the clearance of immune complexes and apoptotic cells, preventing autoimmunity.
• Dysregulated complement activation is a hallmark of systemic lupus erythematosus (SLE) and correlates with disease activity.
• In antiphospholipid syndrome (APS), complement activation is emerging as a key pathogenic mechanism and potential therapeutic target.
• Complement activation contributes to neurological disorders such as Alzheimer's disease and schizophrenia through aberrant synaptic pruning.
• Pregnancy complications, including recurrent fetal loss and preeclampsia, are associated with excessive complement activation.
• Drug carriers and nanoparticles can trigger complement activation, leading to infusion reactions and reduced efficacy.
• Genetic deficiencies in complement components or regulators predispose to infections, autoimmune diseases, or atypical hemolytic uremic syndrome.
• Complement activation is a major area of therapeutic development, with drugs targeting C3, C5, and other components in clinical trials.
• CRISPR-based gene editing enables precise modeling of complement gene mutations to study their functional consequences.
What Happens During complement activation?
Classical Pathway Initiation
In simple terms: The classical pathway is triggered when antibodies bind to a pathogen or antigen, and a recognition molecule called C1q detects these antibodies.
The classical pathway is initiated by the binding of C1q, a subunit of the C1 complex, to the Fc region of antibodies (IgM or IgG) that are bound to antigens on a target surface. This binding activates C1r, which then cleaves and activates C1s. Activated C1s cleaves C4 into C4a and C4b, and C2 into C2a and C2b. C4b and C2a assemble to form the C3 convertase (C4b2a), which cleaves C3 into C3a and C3b, propagating the cascade. This pathway is a key link between adaptive immunity and complement activation, and its dysregulation is implicated in autoimmune diseases such as SLE.
Lectin Pathway Initiation
In simple terms: The lectin pathway starts when pattern-recognition molecules like mannose-binding lectin (MBL) bind to specific sugars on microbial surfaces.
The lectin pathway is activated by the binding of mannose-binding lectin (MBL) or ficolins to carbohydrate patterns on pathogens. MBL-associated serine proteases (MASPs), particularly MASP1 and MASP2, are activated upon binding. MASP2 cleaves C4 and C2 to form the C3 convertase (C4b2a), similar to the classical pathway. MASP1 can directly cleave C3 in some contexts. This pathway provides an antibody-independent means of complement activation and is important for early defense against pathogens, especially in children and immunocompromised individuals.
Alternative Pathway Initiation
In simple terms: The alternative pathway is always active at a low level, and it amplifies complement activation on surfaces that lack protective molecules.
The alternative pathway is initiated by the spontaneous hydrolysis of C3 to C3(H2O), which binds factor B. Factor D cleaves the bound factor B to form the fluid-phase C3 convertase (C3(H2O)Bb), which cleaves C3 to C3b. C3b can then bind to surfaces, where it associates with factor B, and factor D cleaves factor B to form the surface-bound C3 convertase (C3bBb). Properdin stabilizes this convertase. This pathway acts as an amplification loop for all complement activation and is tightly regulated by factors H and I to prevent damage to host cells.
Terminal Pathway and Membrane Attack Complex
In simple terms: All three pathways converge on the terminal pathway, which forms a pore in target cell membranes to kill microbes.
The terminal pathway begins with the cleavage of C5 by the C5 convertase (C4b2a3b or C3bBb3b) into C5a and C5b. C5b initiates the assembly of the membrane attack complex (MAC) by sequentially recruiting C6, C7, C8, and multiple C9 molecules. The MAC forms a pore in the membrane of target cells, leading to cell lysis and death. C5a is a potent anaphylatoxin that recruits inflammatory cells and amplifies the immune response. The terminal pathway is a key effector mechanism of complement activation and is targeted by therapeutic inhibitors such as eculizumab.
Regulation of Complement Activation
In simple terms: Complement activation is kept in check by a set of inhibitory proteins that prevent damage to healthy host cells.
Complement activation is tightly regulated by both soluble and membrane-bound inhibitors to prevent excessive activation and host tissue damage. Soluble regulators include C1-inhibitor (C1INH), which inactivates C1r, C1s, and MASPs; factor H, which accelerates the decay of the alternative pathway C3 convertase and acts as a cofactor for factor I-mediated cleavage of C3b; and C4b-binding protein (C4BP), which regulates the classical and lectin pathways. Membrane-bound regulators include CD55 (decay-accelerating factor), CD46 (membrane cofactor protein), and CD59 (protectin), which inhibits MAC formation. Dysregulation of these regulators is associated with diseases such as atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration.
Key Genes Involved in GO:0006956 complement activation
The following genes encode key proteins involved in complement activation, including recognition molecules, proteases, convertases, and regulators, which are critical for research into the mechanisms and disease associations of GO:0006956.
| Gene | Major Role | Research Relevance |
|---|---|---|
| C1QA | Component of C1q, initiates classical pathway | Deficiency causes SLE-like autoimmunity; target for functional studies |
| C1QB | Component of C1q, initiates classical pathway | Associated with autoimmune diseases; used in KO models |
| C1QC | Component of C1q, initiates classical pathway | Mutations linked to complement deficiencies |
| C1R | Serine protease, activates C1s in classical pathway | Target for inhibiting classical pathway |
| C1S | Serine protease, cleaves C4 and C2 | Key enzyme in classical pathway; drug target |
| C2 | Forms C3 convertase with C4b | Polymorphisms associated with autoimmune diseases |
| C3 | Central component, forms convertases and opsonin | Most abundant complement protein; KO models widely used |
| C4A | Forms C3 convertase, opsonin | Copy number variation linked to SLE |
| C4B | Forms C3 convertase, opsonin | Deficiency predisposes to infections and autoimmunity |
| C5 | Forms MAC, releases C5a anaphylatoxin | Target of eculizumab; KO models for disease |
| CFB | Factor B, forms alternative pathway convertase | Polymorphisms associated with aHUS and AMD |
| CFD | Factor D, cleaves factor B | Essential for alternative pathway; KO models |
| CFH | Factor H, regulates alternative pathway | Mutations cause aHUS; KO models for kidney disease |
| CFI | Factor I, cleaves C3b and C4b | Deficiency leads to uncontrolled activation |
| MASP1 | Mannose-binding lectin-associated serine protease 1 | Activates lectin pathway; KO models |
| MASP2 | Mannose-binding lectin-associated serine protease 2 | Cleaves C4 and C2; deficiency linked to infections |
| MBL2 | Mannose-binding lectin, initiates lectin pathway | Polymorphisms affect susceptibility to infections |
| CFP | Properdin, stabilizes alternative pathway convertase | Deficiency predisposes to Neisseria infections |
How Is complement activation Regulated?
Complement activation is regulated at multiple levels to prevent excessive activation and host tissue damage. Soluble regulators such as C1-inhibitor (C1INH) control the classical and lectin pathways by inactivating C1r, C1s, and MASPs. Factor H and factor I regulate the alternative pathway by accelerating the decay of the C3 convertase and cleaving C3b, respectively. Membrane-bound regulators including CD55, CD46, and CD59 protect host cells from complement-mediated lysis. Additionally, complement activation is influenced by genetic variations in complement genes and regulators, which can predispose to diseases such as atypical hemolytic uremic syndrome and age-related macular degeneration. Therapeutic interventions targeting complement regulators are under development for various diseases.
complement activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| C1Q | SLE, complement deficiency | KO mouse, point mutation knock-in |
| C3 | SLE, aHUS, infections | KO mouse, overexpression |
| C5 | APS, aHUS, neurological disorders | KO mouse, knock-in of human C5 |
| CFH | aHUS, AMD | KO mouse, point mutation knock-in |
| MBL2 | Infections, autoimmune diseases | KO mouse, overexpression |
Complement Activation in Systemic Lupus Erythematosus (SLE)
SLE is a prototypic autoimmune disease characterized by the presence of autoantibodies and immune complex deposition, which lead to complement activation. Excessive complement activation contributes to tissue inflammation and damage in organs such as the kidneys, skin, and joints. Low levels of C3 and C4 are commonly used as biomarkers of disease activity in SLE. Genetic deficiencies in classical pathway components, such as C1q, C1r, C1s, C2, and C4, are strongly associated with SLE, highlighting the role of complement in disease pathogenesis. Targeting complement activation is a therapeutic strategy under investigation for SLE.
Complement Activation in Antiphospholipid Syndrome (APS)
APS is an autoimmune disorder characterized by thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies. Complement activation, particularly through the classical pathway, is emerging as a key pathogenic mechanism in APS. Antiphospholipid antibodies can activate complement, leading to the generation of C5a and MAC, which contribute to thrombosis and fetal loss. Complement inhibition has shown promise in preclinical models of APS, suggesting that targeting complement activation may be a viable therapeutic approach.
Complement Activation in Neurological Disorders
Aberrant complement activation is increasingly recognized as a contributor to neurological disorders, including Alzheimer's disease, schizophrenia, and multiple sclerosis. In the brain, complement proteins such as C1q and C3 mediate synaptic pruning by microglia, and excessive activation can lead to synapse loss and neurodegeneration. Complement activation also plays a role in neuroinflammation and blood-brain barrier dysfunction. Targeting complement activation is being explored as a therapeutic strategy for neurological diseases.
Complement Activation in Pregnancy Complications
Complement activation poses a threat to pregnancy, as excessive activation can lead to fetal loss, preeclampsia, and intrauterine growth restriction. The complement system is involved in placental development and immune tolerance, but dysregulation can cause damage to the placenta and fetus. Antiphospholipid antibodies and other factors can trigger complement activation during pregnancy, contributing to complications. Complement inhibitors have been shown to prevent pregnancy loss in animal models, suggesting potential therapeutic applications.
From complement activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of C3 prevent immune complex deposition in SLE? | C3 knockout mouse |
| Does a point mutation in CFH affect complement regulation? | CFH point mutation knock-in mouse |
| Can overexpression of C1-inhibitor ameliorate APS symptoms? | Transgenic overexpression mouse |
| What is the role of C5a in neuroinflammation? | C5a receptor knockout mouse |
| Does MBL deficiency increase susceptibility to infection? | MBL2 knockout mouse |
| Can CRISPR-mediated knock-in of human C5 model aHUS? | Humanized C5 knock-in mouse |
How to Study the complement activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CH50 hemolytic assay | Functional activity of classical pathway | Diagnosis of complement deficiencies |
| AH50 hemolytic assay | Functional activity of alternative pathway | Screening for alternative pathway defects |
| ELISA for C3a/C5a | Anaphylatoxin levels | Monitoring complement activation in disease |
| Western blot | Cleavage of complement proteins | Assessing activation in vitro |
| Flow cytometry | Complement deposition on cells | Evaluating opsonization |
| RNA-seq | Gene expression profiles | Identifying dysregulated complement genes |
| Proteomics | Protein abundance and modifications | Discovering biomarkers |
| Immunofluorescence | Tissue localization of complement | Studying complement in pathology |
Genetic Approaches to Study Complement Activation
CRISPR-Cas9 genome editing enables the generation of knockout, knock-in, and point mutation models to study the function of complement genes. Knockout models are used to assess the role of specific complement components in disease pathogenesis. Knock-in models allow the expression of human complement proteins or disease-associated variants in mice. Point mutations can be introduced to mimic human genetic variants and study their functional consequences. Overexpression models are useful for investigating the effects of increased complement activity. These genetic tools are essential for dissecting the molecular mechanisms of complement activation and for validating therapeutic targets.
Biochemical and Immunological Assays
Complement activation can be measured using a variety of biochemical and immunological assays. Hemolytic assays (CH50, AH50) measure the functional activity of the classical and alternative pathways, respectively. ELISA-based assays can quantify specific complement activation products, such as C3a, C5a, and sC5b-9, in plasma or serum. Western blotting and immunoprecipitation can detect cleavage products of complement proteins. Flow cytometry can assess complement deposition on cell surfaces. These methods are widely used to evaluate complement activation in clinical samples and experimental models.
Omics and Systems Biology Approaches
Transcriptomic and proteomic analyses provide comprehensive insights into complement gene expression and protein levels in health and disease. RNA sequencing (RNA-seq) can reveal differential expression of complement genes in tissues or cells. Proteomics can identify complement activation products and post-translational modifications. Bioinformatics tools can integrate these data to identify pathways and networks involving complement activation. These approaches are valuable for biomarker discovery and for understanding the systemic effects of complement dysregulation.
Imaging and Functional Studies
Imaging techniques such as immunofluorescence and confocal microscopy can visualize complement deposition in tissues. Live-cell imaging can track the formation of the membrane attack complex on target cells. Functional studies using complement inhibitors or gene editing can assess the consequences of complement activation in cell culture and animal models. These methods help to establish causal relationships between complement activation and disease phenotypes.
How CRISPR Can Be Used to Study GO:0006956 complement activation
Knockout
CRISPR knockout (KO) models are generated by introducing frameshift mutations in complement genes, leading to loss of protein function. KO mice for C3, C4, C5, and other complement components have been instrumental in elucidating their roles in immune defense and disease. For example, C3 KO mice are widely used to study the role of complement in SLE and other autoimmune diseases. KO cell lines can be used for in vitro assays of complement activation. EDITGENE provides custom KO services for complement genes.
Point Mutation
Point mutations can be introduced using CRISPR-Cas9 and homology-directed repair (HDR) to model human genetic variants associated with complement-mediated diseases. For instance, point mutations in CFH are associated with atypical hemolytic uremic syndrome and can be modeled in mice or cell lines to study their functional impact. Point mutation models are valuable for understanding the pathogenicity of specific variants and for testing targeted therapies. EDITGENE offers precise point mutation services.
Knock-in
Knock-in models allow the insertion of human complement genes or tagged versions into the mouse genome, enabling the study of human-specific complement proteins in vivo. For example, human C5 knock-in mice can be used to test anti-C5 therapies. Tagged knock-in models, such as GFP or luciferase fusions, facilitate tracking of complement protein expression and localization. EDITGENE provides knock-in and tagged knock-in services for complement research.
Overexpression
Overexpression models are created by inserting multiple copies of a complement gene or using strong promoters to drive high-level expression. These models are useful for studying the effects of complement overactivation, as seen in autoimmune diseases and pregnancy complications. For example, overexpression of C1-inhibitor can protect against complement-mediated damage. EDITGENE offers overexpression services for complement genes in cell lines and animal models.
How EDITGENE Supports complement activation Research
Researchers studying complement activation-related genes often need to determine whether a candidate gene is causally involved in disease pathogenesis or whether a specific genetic variant alters protein function. CRISPR-based genome editing provides a powerful approach to create precise genetic models that can answer these questions. EDITGENE specializes in providing custom CRISPR services for complement research, including knockout, point mutation, knock-in, overexpression, and library screening, supported by advanced bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for complement activation research.
Frequently Asked Questions About complement activation
What is complement activation?
Complement activation (GO:0006956) is the biological process that triggers the complement cascade, leading to the killing of microbes, clearance of immune complexes, and regulation of immune responses.
What are the three pathways of complement activation?
The three pathways are the classical pathway, initiated by antibody-antigen complexes; the lectin pathway, initiated by mannose-binding lectin; and the alternative pathway, initiated by spontaneous C3 hydrolysis.
What genes are involved in complement activation?
Key genes include C1QA, C1QB, C1QC, C1R, C1S, C2, C3, C4A, C4B, C5, CFB, CFD, CFH, CFI, MASP1, MASP2, MBL2, and CFP.
How is complement activation regulated?
Complement activation is regulated by inhibitors such as C1-inhibitor, factor H, factor I, CD55, CD46, and CD59, which prevent excessive activation and host tissue damage.
What diseases are associated with complement activation?
Diseases include systemic lupus erythematosus, antiphospholipid syndrome, atypical hemolytic uremic syndrome, neurological disorders, and pregnancy complications.
How can CRISPR be used to study complement activation?
CRISPR can generate knockout, knock-in, point mutation, and overexpression models to study the function of complement genes and their role in disease.
What is the membrane attack complex?
The membrane attack complex (MAC) is a pore formed by C5b, C6, C7, C8, and C9 that lyses target cells, representing the terminal step of complement activation.
What is the role of C3 in complement activation?
C3 is the central component of the complement system; its cleavage products C3a and C3b drive opsonization, inflammation, and formation of the C5 convertase.
How is complement activation measured?
Complement activation can be measured by hemolytic assays (CH50, AH50), ELISA for activation products (C3a, C5a, sC5b-9), and flow cytometry for deposition on cells.
What are the therapeutic targets in complement activation?
Therapeutic targets include C3, C5, C5a receptor, factor B, and factor D, with drugs like eculizumab approved for complement-mediated diseases.
Conclusion
Complement activation (GO:0006956) is a vital biological process that bridges innate and adaptive immunity, with profound implications for human health and disease. Its dysregulation contributes to a spectrum of disorders, from autoimmune diseases to neurological conditions and pregnancy complications. Understanding the molecular mechanisms, key genes, and regulatory networks of complement activation is essential for developing targeted therapies. CRISPR-based genome editing offers unprecedented opportunities to model complement gene variants and dissect their functions in disease. EDITGENE provides comprehensive CRISPR services to support complement research, from knockout and knock-in models to library screening and bioinformatics, empowering researchers to advance this critical field.
References
- 1. Weinstein A et al.. 2021. A Review of Complement Activation in SLE.. Curr Rheumatol Rep 23(3):16 PMID: 33569681
- 2. Noris M et al.. 2013. Overview of complement activation and regulation.. Semin Nephrol 33(6):479-92 PMID: 24161035
- 3. Dijkstra DJ et al.. 2019. Complement activation and regulation in rheumatic disease.. Semin Immunol 45:101339 PMID: 31718864
- 4. Goldberg BS et al.. 2020. Antibody-mediated complement activation in pathology and protection.. Immunol Cell Biol 98(4):305-317 PMID: 32142167
- 5. Moghimi SM et al.. 2020. Complement activation by drug carriers and particulate pharmaceuticals: Principles, challenges and opportunities.. Adv Drug Deliv Rev 157:83-95 PMID: 32389761
- 6. Venturelli V et al.. 2024. Can complement activation be the missing link in antiphospholipid syndrome?. Rheumatology (Oxford) 63(12):3243-3254 PMID: 38483257
- 7. Girardi G. 2018. Complement activation, a threat to pregnancy.. Semin Immunopathol 40(1):103-111 PMID: 28900713
- 8. Ziabska K et al.. 2021. Aberrant Complement System Activation in Neurological Disorders.. Int J Mol Sci 22(9) PMID: 33925147
